• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ETHICON INC. ETHILON NYLON SUTURE UNKNOWN PRODUCT SUTURE, NONABSORBABLE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ETHICON INC. ETHILON NYLON SUTURE UNKNOWN PRODUCT SUTURE, NONABSORBABLE Back to Search Results
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Unspecified Infection (1930); Pain (1994)
Event Type  Injury  
Manufacturer Narrative

(b)(4). This report is related to a journal article, therefore no product will be returned for analysis and the batch history records cannot be reviewed as the lot number has not been provided. Attempts are being made to obtain the following information. To date no response has been provided. If further details are received at a later date a supplemental medwatch will be sent. Were the cases discussed in this article previously reported to ethicon? if yes, please provide a complaint reference number. Does the surgeon believe that ethicon products involved caused and/or contributed to the post-operative complications described in the article? does the surgeon believe there was any deficiency with the ethicon products used in this procedure? citation: world neurosurg. (2019) 123:390-401. / https://doi. Org/10. 1016/j. Wneu. 2018. 11. 135. (b)(4).

 
Event Description

It was reported via journal article: "title: surgical protocol for infections, nonhealing wound prophylaxis, and analgesia: development and implementation for posterior spinal fusions". Author(s): evgenii belykh, alessandro carotenuto, andrey a. Kalinin, serik k. Akshulakov, talgat kerimbayev, vladislav e. Borisov, marat a. Aliyev, peter nakaji, mark c. Preul, vadim a. Byvaltsev. Citation: world neurosurg. (2019) 123:390-401. / https://doi. Org/10. 1016/j. Wneu. 2018. 11. 135. The purpose of this prospective longitudinal controlled single-center study was to analyze the effects of a surgical protocol for infections, nonhealing wound prophylaxis, and analgesia (spina) among patients who underwent posterior spinal fusion at a single tertiary-care neurosurgical center. In 2015, a total of 148 patients underwent decompression and fusion surgeries on the lumbar spine for various degenerative spine diseases. The patients were divided into two: first cohort of patients [control group, (n=35 (n=30 female, n=5 male, median age 45 years (range 31-54 years), median bmi 25. 9 kg/m2))] was enrolled prospectively during a period of 3 months; and the second cohort [study group, (n=113 (n=74 female, n=37 male, median age 40 years (range 37-54 years), median bmi 27. 8 kg/m2))] was enrolled during a 1-year period after the implementation of the spina. In both groups, surgical wound closure was strictly performed in layers under the optical magnification of the operative microscope with use of atraumatic needle sutures. Paraspinal muscles were closed with an interrupted suture without overtightening the loops with use of 1-0 or 2-0 absorbable sutures (vicryl, ethicon). The deep fascia was closed with interrupted sutures placed at a 0. 5-mm interval with use of 1-0 or 2-0 sutures (vicryl or pds ii, ethicon). Subcutaneous fat was sutured in 1 or more layers, depending on the thickness, with inverted interrupted 3-0 sutures with prolonged resorption time (e. G. , vicryl). The dermal layer was closed with an overlapping continuous suture or an intradermal continuous suture with use of nonabsorbable 3-0 (prolene 3-0, ethilon 3-0, ethicon) or absorbable 4-0 monofilament (monocryl 4-0, ethicon) and 4-0 plus dermabond (ethicon) on skin. Postoperative complications included minor surgical site infections (ssis) (n=23) which were successfully managed with drainage of the surgical wound and administration of local antibiotic ointment, in addition to administration of the standard postoperative systemic antibiotics; and pain in the surgical site (n=?) wherein injections of narcotic (tramadol intramuscular 100 mg in 2 ml) and nonnarcotic analgesics (ketoprofen intramuscular 100 mg in 2 ml) were commonly given. Implementation of the surgical protocol for infections, nonhealing wound prophylaxis, and analgesia for posterior interventions allowed us to optimize the wound healing process, reduce the rate of minor postoperative ssis, and significantly improve early clinical outcomes. Essential components of the protocol were careful microsurgical hemostasis, layered wound closure with modern sutures, effectively chosen perioperative antibacterial prophylaxis, and local anesthesia.

 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand NameETHILON NYLON SUTURE UNKNOWN PRODUCT
Type of DeviceSUTURE, NONABSORBABLE
Manufacturer (Section D)
ETHICON INC.
p.o. box 151, route 22 west
somerville NJ 08876
Manufacturer (Section G)
ETHICON INC.
Manufacturer Contact
kara ditty-bovard
p.o. box 151, route 22 west
somerville, NJ 08876
6107428552
MDR Report Key9950322
MDR Text Key193638657
Report Number2210968-2020-02937
Device Sequence Number1
Product Code GAR
Combination Product (Y/N)N
Reporter Country CodeRS
PMA/PMN NumberNA
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type FOREIGN,LITERATURE
Reporter Occupation
Type of Report Initial
Report Date 03/18/2020
1 Device Was Involved in the Event
1 Patient Was Involved in the Event
Date FDA Received04/10/2020
Is This An Adverse Event Report? Yes
Is This A Product Problem Report? No
Device Operator HEALTH PROFESSIONAL
Was Device Available For Evaluation? No
Is The Reporter A Health Professional?
Was the Report Sent to FDA?
Event Location No Information
Date Manufacturer Received03/18/2020
Was Device Evaluated By Manufacturer? Device Not Returned To Manufacturer
Is The Device Single Use? Yes
Is this a Reprocessed and Reused Single-Use Device?
Type of Device Usage Initial

Patient TREATMENT DATA
Date Received: 04/10/2020 Patient Sequence Number: 1
-
-